Efficacy of Pyrotinib combined with Trastuzumab in the treatment of patients with human epidermal growth factor receptor-2 positive breast cancer
Compared with Trastuzumab alone, a combined regimen of Pyrrolitinib and Trastuzumab is equally safe, and improving immune function, reducing the level of tumor markers, and improving tumor response in patients with HER-2 positive BC.
Authors
- Bin Tang (ORCID: https://orcid.org/0000-0001-8389-5759)
- Qianxing Mo (ORCID: https://orcid.org/0000-0002-0021-7694)
- Liming Xie (ORCID: https://orcid.org/0000-0001-8190-8325)
- Lingling Zhang (ORCID: https://orcid.org/0009-0005-6902-3475)
- Xiuwen Yi
- Yulan Tang
Institutions
- First Affiliated Hospital of University of South China (CN)
- University of South China (CN)
Publication Details
- Journal
- Pakistan Journal of Medical Sciences
- Published
- 2025-06-03
- DOI
- https://doi.org/10.12669/pjms.41.6.11682
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00